Quantifying Uric Acid Excretion With RDEA3170, Febuxostat and Dapagliflozin

Trial Profile

Quantifying Uric Acid Excretion With RDEA3170, Febuxostat and Dapagliflozin

Recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Nov 2017

At a glance

  • Drugs Dapagliflozin (Primary) ; Febuxostat (Primary) ; Verinurad (Primary)
  • Indications Hyperuricaemia
  • Focus Pharmacokinetics
  • Sponsors AstraZeneca
  • Most Recent Events

    • 02 Nov 2017 Planned End Date changed from 15 Mar 2018 to 16 Mar 2018.
    • 02 Nov 2017 Planned primary completion date changed from 15 Mar 2018 to 16 Mar 2018.
    • 02 Nov 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top